This company listing is no longer active

This company may still be operating, however this listing is no longer active. Find out why through their latest events.

G1 Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

G1 Therapeutics CEO'su Jack Bailey, Jan2021 tarihinde atandı, in görev süresi 3.67 yıldır. in toplam yıllık tazminatı $ 3.25M olup, şirket hissesi ve opsiyonları dahil olmak üzere 24.5% maaş ve 75.5% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.37% ine doğrudan sahiptir ve bu hisseler € 1.26M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.7 yıl ve 6 yıldır.

Anahtar bilgiler

Jack Bailey

İcra Kurulu Başkanı

US$3.3m

Toplam tazminat

CEO maaş yüzdesi	24.5%
CEO görev süresi	3.7yrs
CEO sahipliği	0.4%
Yönetim ortalama görev süresi	3.7yrs
Yönetim Kurulu ortalama görev süresi	6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Jack Bailey'un ücretlendirmesi G1 Therapeutics'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$45m
Mar 31 2024	n/a	n/a	-US$31m
Dec 31 2023	US$3m	US$795k	-US$48m
Sep 30 2023	n/a	n/a	-US$71m
Jun 30 2023	n/a	n/a	-US$78m
Mar 31 2023	n/a	n/a	-US$126m
Dec 31 2022	US$3m	US$764k	-US$148m
Sep 30 2022	n/a	n/a	-US$154m
Jun 30 2022	n/a	n/a	-US$171m
Mar 31 2022	n/a	n/a	-US$171m
Dec 31 2021	US$9m	US$735k	-US$148m
Sep 30 2021	n/a	n/a	-US$134m
Jun 30 2021	n/a	n/a	-US$103m
Mar 31 2021	n/a	n/a	-US$95m
Dec 31 2020	US$2m	n/a	-US$99m

Tazminat ve Piyasa: Jack 'nin toplam tazminatı ($USD 3.25M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 1.03M ).

Tazminat ve Kazançlar: Jack şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Jack Bailey (59 yo)

3.7yrs

Görev süresi

US$3,250,658

Tazminat

Mr. John E. Bailey, also known as Jack, Jr. has been Director at G1 Therapeutics, Inc. since March 12, 2020. He serves as President and Chief Executive Officer at G1 Therapeutics Inc. since January 1, 2021...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Bailey	CEO, President & Director	3.7yrs	US$3.25m	0.37% € 1.3m
Rajesh Malik	Chief Medical Officer	10.2yrs	US$1.11m	0.17% € 561.7k
Mark Avagliano	Chief Business Officer	5.2yrs	US$1.17m	0.049% € 167.2k
John Umstead	Chief Financial Officer	1.5yrs	Veri yok	0.037% € 124.2k
Terry Murdock	Chief Operating Officer	5.7yrs	US$2.75m	0.040% € 135.8k
William Roberts	Vice President of Investor Relations & Corporate Communications	3.7yrs	Veri yok	Veri yok
Monica Thomas	Chief Legal & People Officer	1.3yrs	Veri yok	0.013% € 44.0k
Evan Hicks	Vice President of Marketing	no data	Veri yok	Veri yok
Andrew Perry	Chief Commercial Officer	3.1yrs	US$3.39m	0.027% € 91.4k
Jeff Macdonald	Senior Director of Investor Relations & Corporate Communications	no data	Veri yok	Veri yok

3.7yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim: G1H 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.7 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
John Bailey	CEO, President & Director	4.5yrs	US$3.25m	0.37% € 1.3m
Seth Rudnick	Member of Clinical Advisory Board	no data	US$456.29k	Veri yok
Glenn Muir	Independent Director	9yrs	US$172.85k	0.35% € 1.2m
Joseph Bailes	Scientific & Clinical Advisor	no data	Veri yok	Veri yok
George Demetri	Scientific & Clinical Advisor	no data	Veri yok	Veri yok
Cynthia Flowers	Independent Director	6.3yrs	US$162.85k	0.030% € 102.0k
Garry Nicholson	Independent Chairman of the Board	6yrs	US$195.35k	0.027% € 92.4k
Gary Lyman	Scientific & Clinical Advisor	no data	Veri yok	Veri yok
Norman Sharpless	Director	2.2yrs	US$135.35k	0% € 0
Kwok-Kin Wong	Co-Founder & Member of Scientific Advisory Board	no data	Veri yok	Veri yok
Donald McDonnell	Scientific & Clinical Advisor	no data	Veri yok	Veri yok
Geoffrey Shapiro	Scientific & Clinical Advisor	no data	Veri yok	Veri yok

6.0yrs

Ortalama Görev Süresi

67yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: G1H 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 6 yıldır).

This company listing is no longer active

G1 Therapeutics Yönetim

Yönetim kriter kontrolleri 2/4

Anahtar bilgiler

Son yönetim güncellemeleri

CEO, President & Director recently sold €165k worth of stock

G1 Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023

G1 Therapeutics Announces Appointment of Monica Thomas as Chief Compliance Officer

CEO, President & Director recently sold €206k worth of stock

G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors

Recent updates

G1 Therapeutics, Inc.(NasdaqGS:GTHX) dropped from NASDAQ Composite Index

New minor risk - Shareholder dilution

Second quarter 2024 earnings released: US$0.10 loss per share (vs US$0.17 profit in 2Q 2023)

Pharmacosmos Therapeutics Inc. entered into a definitive merger agreement to acquire G1 Therapeutics, Inc. (NasdaqGS:GTHX) for approximately $390 million.

G1 Therapeutics, Inc. to Report Q2, 2024 Results on Aug 08, 2024

G1 Therapeutics, Inc. Provides Update on Phase 3 Presents 2 Trial in Patients Receiving Trilaciclib Prior to First Line Chemotherapy in Metastatic Triple Negative Breast Cancer

G1 Therapeutics Announces Upcoming Presentation at the 2024 American Society of Clinical Oncology Meeting

CEO, President & Director recently sold €165k worth of stock

Forecast to breakeven in 2026

First quarter 2024 earnings released: US$0.20 loss per share (vs US$0.53 loss in 1Q 2023)

G1 Therapeutics, Inc., Annual General Meeting, Jun 13, 2024

G1 Therapeutics, Inc. to Report Q1, 2024 Results on May 01, 2024

Forecast breakeven date pushed back to 2026

Full year 2023 earnings released: US$0.93 loss per share (vs US$3.38 loss in FY 2022)

G1 Therapeutics, Inc. Provides Earnings Guidance for the Full Year 2024

G1 Therapeutics, Inc. to Report Q4, 2023 Results on Feb 28, 2024

G1 Therapeutics to Continue Pivotal Phase 3 Trial of Trilaciclib in Metastatic Triple Negative Breast Cancer Following Interim Analysis by Independent Data Monitoring Committee

Forecast to breakeven in 2025

G1 Therapeutics, Inc. Announces Updates, Including Encouraging Preliminary Overall Survival Data from the Ongoing Phase 2 Trial of Trilaciclib in Combination with the ADC Sacituzumab Govitecan in Patients with TNBC

Third quarter 2023 earnings released: US$0.35 loss per share (vs US$0.59 loss in 3Q 2022)

G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023

G1 Therapeutics, Inc. Lowers Net Revenue Guidance for the Full Year 2023

G1 Therapeutics, Inc. to Report Q3, 2023 Results on Nov 01, 2023

New major risk - Share price stability

G1 Therapeutics, Inc. Announces Resignation of Mark A. Velleca from the Board of Directors, Effective as of September 30, 2023

New minor risk - Market cap size

New minor risk - Profitability

No longer forecast to breakeven

Second quarter 2023 earnings released: EPS: US$0.17 (vs US$0.92 loss in 2Q 2022)

G1 Therapeutics, Inc. Provides Financial Guidance for the Full Year 2023

G1 Therapeutics, Inc. to Report Q2, 2023 Results on Aug 02, 2023

G1 Therapeutics Announces Appointment of Monica Thomas as Chief Compliance Officer

Forecast to breakeven in 2025

Forecast to breakeven in 2025

G1 Therapeutics, Inc. Presents New Results from Phase 2 Trial Confirm Benefit of Trilaciclib in Reducing Adverse Events Related to an Antibody Drug Conjugate

First quarter 2023 earnings released: US$0.53 loss per share (vs US$1.15 loss in 1Q 2022)

G1 Therapeutics, Inc. Reiterates Earnings Guidance for the Full Year 2023

Full year 2022 earnings released: US$3.38 loss per share (vs US$3.54 loss in FY 2021)

G1 Therapeutics, Inc. Announces Top Line Results from Pivotal Phase 3 Trial of Trilaciclib in Patients Receiving Triplet Therapy with Folfoxiri + Bevacizumab for Metastatic Colorectal Cancer (CRC) (Preserve 1)

CEO, President & Director recently sold €206k worth of stock

G1 Therapeutics, Inc. Announces Upcoming 2023 Readouts from its Phase 2 and Pivotal Phase 3 Clinical Trials of Trilaciclib

G1 Therapeutics Provides Initial Update on Phase 2 Bladder Cancer Trial; Progression Free Survival (Pfs) Data Expected in Mid-2023

G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Mechanism of Action Trial in Early-Stage Triple Negative Breast Cancer

G1 Therapeutics, Inc. has completed a Follow-on Equity Offering in the amount of $50.05 million.

Third quarter 2022 earnings released: US$0.59 loss per share (vs US$1.00 loss in 3Q 2021)

G1 Therapeutics, Inc. Announces Initial Results from Phase 2 Trial Demonstrate Potential of Trilaciclib to Reduce Adverse Events Related to an Antibody Drug Conjugate (Adc)

G1 Therapeutics Announces Investigator Initiated Study of Trilaciclib and Lurbinectedin in Patients with Extensive Stage Small Cell Lung Cancer

G1 Therapeutics Completes Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Triple Negative Breast Cancer (Tnbc)

Second quarter 2022 earnings released: US$0.92 loss per share (vs US$0.94 loss in 2Q 2021)

G1 Therapeutics Announces Addition of Norman E. Sharpless to Board of Directors

G1 Therapeutics, Inc. to Report Q2, 2022 Results on Aug 03, 2022

G1 Therapeutics, Inc. Announces Approval of COSELA by China National Medical Products Administration

G1 Therapeutics, Inc. Announces Resignation of Willie A. Deese from the Board

G1 Therapeutics, Inc. Announces Completion of Enrollment in Global Multi-Center Phase 3 Clinical Trial of Trilaciclib in Patients with Metastatic Colorectal Cancer

G1 Therapeutics, Inc. Demonstrate Trilaciclib Helps Protect Against Severe Neutropenia, Severe Anemia, and Severe Thrombocytopenia When Given to Extensive-Stage Small Cell Lung Cancer Patients Prior to Chemotherapy

G1 Therapeutics, Inc. Announces Results of A Retrospective

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

G1 Therapeutics, Inc. to Report Q4, 2021 Results on Feb 23, 2022

G1 Therapeutics, Inc. Initiates Phase 2 Trial to Support Antitumor Mechanism of Action of Trilaciclib in Tumor Microenvironment

G1 Therapeutics, Inc. Announces Initiation of New Phase 2 Trial of Trilaciclib in Combination with Antibody-Drug Conjugate, Trodelvy® (Sacituzumab Govitecan-Hziy) in Patients with Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer

Third quarter 2021 earnings released: US$1.00 loss per share (vs US$0.31 loss in 3Q 2020)

G1 Therapeutics Grants New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)

G1 Therapeutics, Inc. Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer

G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA in Bladder Cancer

G1 Therapeutics Presents Phase 1 Data At ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant

G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA(trilaciclib) in Non-Small Cell Lung Cancer

G1 Therapeutics, Inc. Announces Initiation of Phase 3 Registrational Study of COSELA (trilaciclib) in Triple-Negative Breast Cancer

G1 Therapeutics, Inc. Announces Publication of Pooled Results from Pivotal Clinical Program of Cosela™ (Trilaciclib) in Clinical Lung Cancer